Nurs Womens Health. 2020 Oct;24(5):377-382. doi: 10.1016/j.nwh.2020.07.006. Epub 2020 Sep 2.
In 2019, the U.S. Food and Drug Administration approved cefiderocol, a new treatment option for individuals with complicated urinary tract infections. Cefiderocol is a cephalosporin antibiotic indicated for use in adults 18 years or older who have minimal treatment options due to resistance for complicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The recommended dose of cefiderocol is 2 g intravenously every 8 hours infused over 3 hours. The dose is adjusted for individuals with creatinine clearance of less than 60 ml/min or greater than 120 ml/min. Gastrointestinal symptoms such as diarrhea and constipation are the most common adverse events reported by individuals taking cefiderocol.
2019 年，美国食品和药物管理局批准了头孢地尔，这是一种新的治疗选择，适用于因大肠杆菌、肺炎克雷伯菌、奇异变形杆菌、铜绿假单胞菌和阴沟肠杆菌复合物引起的复杂性尿路感染，且对治疗耐药的 18 岁及以上成人。头孢地尔的推荐剂量为每 8 小时静脉注射 2g，输注时间为 3 小时。对于肌酐清除率低于 60ml/min 或大于 120ml/min 的个体，剂量需要调整。腹泻和便秘等胃肠道症状是接受头孢地尔治疗的个体最常报告的不良事件。
